• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Hinge Health Inc.

    8/13/25 6:30:51 AM ET
    $HNGE
    EDP Services
    Technology
    Get the next $HNGE alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Hinge Health, Inc.

    (Name of Issuer)


    Class A Common Stock, par value $0.00001 per share

    (Title of Class of Securities)


    433313103

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    433313103


    1Names of Reporting Persons

    Alkeon Capital Management LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,591,104.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,591,104.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,591,104.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.7 %
    12Type of Reporting Person (See Instructions)

    IA, OO

    Comment for Type of Reporting Person:  Includes 1,215,093 shares of Class A Common Stock (as defined in Item 2(a)) issuable upon conversion of Class B Common Stock (as defined in Item 2(a)).


    SCHEDULE 13G

    CUSIP No.
    433313103


    1Names of Reporting Persons

    Panayotis D. Sparaggis
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,591,104.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,591,104.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,591,104.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.7 %
    12Type of Reporting Person (See Instructions)

    HC, IN

    Comment for Type of Reporting Person:  Includes 1,215,093 shares of Class A Common Stock issuable upon conversion of Class B Common Stock.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Hinge Health, Inc.
    (b)Address of issuer's principal executive offices:

    455 Market Street, Suite 700, San Francisco, CA 94105
    Item 2. 
    (a)Name of person filing:

    This statement is filed by: (i) Alkeon Capital Management LLC ("Alkeon"), a Delaware limited liability company and the investment manager to certain funds (the "Alkeon Funds"), with respect to the shares of Class A Common Stock, par value $0.00001 per share ("Class A Common Stock") of Hinge Health, Inc., a Delaware corporation (the "Company") directly held by, and the shares of Class A Common Stock issuable upon conversion of the shares the Company's Class B Common Stock, par value $0.00001 per share (the "Class B Common Stock") directly held by, the Alkeon Funds; and (ii) Panayotis D. Sparaggis ("Mr. Sparaggis"), the Founder and Managing Director of Alkeon, with respect to the shares of Class A Common Stock directly held by, and the shares of Class A Common Stock issuable upon conversion of the shares of Class B Common Stock directly held by, the Alkeon Funds. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the securities reported herein.
    (b)Address or principal business office or, if none, residence:

    The address of the business office of each of the Reporting Persons is 350 Madison Avenue, 20th Floor, New York, NY 10017.
    (c)Citizenship:

    The Investment Manager is a Delaware limited liability company. Mr. Sparaggis is a citizen of the United States.
    (d)Title of class of securities:

    Class A Common Stock, par value $0.00001 per share
    (e)CUSIP No.:

    433313103
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 26,799,441 shares of Class A Common Stock outstanding as reported in the Company's Prospectus filed pursuant to Rule 424(b)(4) with the Securities and Exchange Commission on May 23, 2025, and in the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 23, 2025, after giving effect to the completion of the offering and the full exercise of the underwriters' over-allotment option, all as described therein, and assumes the conversion of the shares of Class B Common Stock held by the Alkeon Funds.
    (b)Percent of class:

    5.7%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

     (ii) Shared power to vote or to direct the vote:

    The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

     (iii) Sole power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

     (iv) Shared power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    See Item 2(a). The Alkeon Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, shares of Class A Common Stock.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    Not Applicable

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Alkeon Capital Management LLC
     
    Signature:/s/ Jennifer Shufro
    Name/Title:Jennifer Shufro, Compliance Officer
    Date:08/13/2025
     
    Panayotis D. Sparaggis
     
    Signature:/s/ Panayotis D. Sparaggis
    Name/Title:Panayotis D. Sparaggis, Individually
    Date:08/13/2025
    Exhibit Information

    Exhibit 99.1: Joint Filing Agreement

    Get the next $HNGE alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HNGE

    DatePrice TargetRatingAnalyst
    7/14/2025$58.00Mkt Outperform
    Citizens JMP
    6/16/2025Outperform
    William Blair
    6/16/2025$48.00Buy
    Truist
    6/16/2025$48.00Buy
    Stifel
    6/16/2025$45.00Outperform
    Raymond James
    6/16/2025$41.00Overweight
    Piper Sandler
    6/16/2025$46.00Overweight
    Morgan Stanley
    6/16/2025$47.00Buy
    Needham
    More analyst ratings

    $HNGE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO & Co-Founder Perez Daniel Antonio exercised 35,470 shares at a strike of $1.08 (SEC Form 4)

    4 - Hinge Health, Inc. (0001673743) (Issuer)

    8/6/25 4:13:45 PM ET
    $HNGE
    EDP Services
    Technology

    $HNGE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citizens JMP initiated coverage on Hinge Health with a new price target

    Citizens JMP initiated coverage of Hinge Health with a rating of Mkt Outperform and set a new price target of $58.00

    7/14/25 8:51:47 AM ET
    $HNGE
    EDP Services
    Technology

    William Blair initiated coverage on Hinge Health

    William Blair initiated coverage of Hinge Health with a rating of Outperform

    6/16/25 7:49:34 AM ET
    $HNGE
    EDP Services
    Technology

    Truist initiated coverage on Hinge Health with a new price target

    Truist initiated coverage of Hinge Health with a rating of Buy and set a new price target of $48.00

    6/16/25 7:49:23 AM ET
    $HNGE
    EDP Services
    Technology

    $HNGE
    Financials

    Live finance-specific insights

    View All

    Hinge Health Reports Second Quarter 2025 Financial Results

    Hinge Health, Inc. (NYSE:HNGE) today announced financial results for the second quarter ended June 30, 2025. "In Q2 we delivered year-over-year revenue growth of 55% and a strong free cash flow margin, underlining the market's embrace of our AI-powered platform," said Daniel Perez, Co-Founder and CEO, Hinge Health. "The journey of automating healthcare delivery will be challenging, but we're excited about our momentum and are moving with haste to capture this opportunity." Second Quarter 2025 Financial Highlights: Revenue increased 55% year-over-year to $139.1 million compared to revenue of $89.8 million in Q2 2024. GAAP gross margin was 70% compared to 74% in Q2 2024. Non-GAAP gr

    8/5/25 4:05:00 PM ET
    $HNGE
    EDP Services
    Technology

    Hinge Health to announce second quarter 2025 financial results on August 5, 2025

    Hinge Health, Inc. (NYSE:HNGE) announced today that it will report its financial results for the quarterly period ended June 30, 2025, after the close of the market on Tuesday, August 5, 2025. Hinge Health will also host an earnings conference call to discuss its results and guidance at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) the same day. The live audio webcast of the earnings conference call will be available on the Hinge Health Investor Relations website at ir.hingehealth.com. A replay of the webcast will be available on the same website shortly after its completion. About Hinge Health Hinge Health is focused on scaling and automating the delivery of health care, starting w

    7/8/25 4:30:00 PM ET
    $HNGE
    EDP Services
    Technology

    $HNGE
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Hinge Health Inc.

    SCHEDULE 13G - Hinge Health, Inc. (0001673743) (Subject)

    8/14/25 5:37:04 PM ET
    $HNGE
    EDP Services
    Technology

    SEC Form SCHEDULE 13G filed by Hinge Health Inc.

    SCHEDULE 13G - Hinge Health, Inc. (0001673743) (Subject)

    8/14/25 4:56:48 PM ET
    $HNGE
    EDP Services
    Technology

    SEC Form SCHEDULE 13G filed by Hinge Health Inc.

    SCHEDULE 13G - Hinge Health, Inc. (0001673743) (Subject)

    8/14/25 4:35:39 PM ET
    $HNGE
    EDP Services
    Technology

    $HNGE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hinge Health Reports Second Quarter 2025 Financial Results

    Hinge Health, Inc. (NYSE:HNGE) today announced financial results for the second quarter ended June 30, 2025. "In Q2 we delivered year-over-year revenue growth of 55% and a strong free cash flow margin, underlining the market's embrace of our AI-powered platform," said Daniel Perez, Co-Founder and CEO, Hinge Health. "The journey of automating healthcare delivery will be challenging, but we're excited about our momentum and are moving with haste to capture this opportunity." Second Quarter 2025 Financial Highlights: Revenue increased 55% year-over-year to $139.1 million compared to revenue of $89.8 million in Q2 2024. GAAP gross margin was 70% compared to 74% in Q2 2024. Non-GAAP gr

    8/5/25 4:05:00 PM ET
    $HNGE
    EDP Services
    Technology

    Hinge Health to announce second quarter 2025 financial results on August 5, 2025

    Hinge Health, Inc. (NYSE:HNGE) announced today that it will report its financial results for the quarterly period ended June 30, 2025, after the close of the market on Tuesday, August 5, 2025. Hinge Health will also host an earnings conference call to discuss its results and guidance at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) the same day. The live audio webcast of the earnings conference call will be available on the Hinge Health Investor Relations website at ir.hingehealth.com. A replay of the webcast will be available on the same website shortly after its completion. About Hinge Health Hinge Health is focused on scaling and automating the delivery of health care, starting w

    7/8/25 4:30:00 PM ET
    $HNGE
    EDP Services
    Technology

    Hinge Health Announces HingeSelect - a High-performance Network Delivering Unified Musculoskeletal Care

    Combined with Hinge Health's AI-powered exercise therapy program, HingeSelect adds access to high-quality in-person providers for members at up to 50% below PPO rates Hinge Health, Inc. (NYSE:HNGE), today announced the launch of HingeSelect, a high-performance provider network for musculoskeletal (MSK) care. Hinge Health's technology and in-house orthopedic physicians triage and direct downstream care, prioritizing the most appropriate evidence-based treatment. When in-person care, such as imaging or injections is required, members are seamlessly connected to pre-vetted providers at up to 50% below PPO rates. Combined with Hinge Health's AI-powered digital exercise therapy, HingeSelect pr

    6/17/25 9:00:00 AM ET
    $HNGE
    EDP Services
    Technology